Study of adebrelimab for advanced small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how well adebrelimab works and how safe it is in real-world settings for people with advanced small cell lung cancer that has spread. It may help doctors understand if this treatment is a good option for patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced small cell lung cancer that has spread (extensive-stage).
- You are 18 years or older.
- Your doctor decides you can have or are already taking adebrelimab.
- You are not currently taking other immune-modulating drugs.
- You are not in another interventional study.
- You do not have another type of cancer.
- Your key medical records are complete.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a drug called adebrelimab (a type of immunotherapy) before surgery for people with early-stage small cell lung cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
This trial tests a combination of three drugs (adebrelimab, irinotecan liposome, and famitinib) for people with extensive-stage small cell lung cancer whose disease got worse after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This study is testing a drug called adebrelimab for people with advanced small cell lung cancer. It collects real-world information on how well the treatment works and how it affects patients.
This study tests a drug called adebrelimab, used alone or with other treatments, for people with advanced solid tumors, including extensive-stage small cell lung cancer. It aims to see if adding this drug helps control the cancer.
This study tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation treatment for patients with advanced non-small cell lung cancer that cannot be surgically removed. The goal is to improve how well treatment works and help patients live longer.
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
Hear when a new Small Cell Lung Cancer (SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.